Senior Director, New Initiatives, Innovation Hub at Biogen

Jane [Relton] Rhodes, PhD, MBA, is Senior Director of New Initiatives in the Value Based Medicine group at Biogen. Dr. Rhodes leads a number of initiatives that employ digital solutions to help transform the care of patients with neurological diseases by improving outcomes and demonstrating value to patients and providers. Dr. Rhodes began her scientific career in the field of neurology drug discovery research, and worked on novel therapies for stroke, MS, ALS, Parkinson’s disease and Alzheimer’s disease.

TRNDS Speaker Spotlight

Why are you participating in TRNDS 2017?

Researchers at the University of Rochester are leaders in clinical innovation and we, at Biogen, have an interest in incorporating technology into the practice of Neurology to improve patient outcomes. This meeting promises to be an interesting forum for discussion and idea generation.

What do you see as the biggest opportunities to accelerate rare disease therapeutic development?

Leveraging technology to enable the routine collection of standardized clinical measures.

What are some potential applications of technology in rare disease research?

Passive monitoring of children with Spinal Muscular Atrophy (SMA).

Tell us a bit about Biogen’s work to foster innovation in clinical trials.

Biogen has a large, ongoing initiative to demonstrate the feasibility and utility of collecting standardized clinical data during routine clinical practice that can be used for research purposes. This initiative, called MS PATHS [Partners Advancing Technology and Healthcare Solutions] brings together a network of 10 leading MS centers who have implemented standardized data collection methods into their MS practices. The network uses technology solutions to enable data acquisition, without additional burden to HCPs, and sharing of de-identified data across the centers for research purposes. The MS clinic at URMC is participating in this program, with Dr. Megan Hyland spearheading this collaboration with Biogen.